11 completed, 3 unknown, 2 not yet recruiting, 2 recruiting. 20 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 20 | Completed 11, Unknown 3, Not yet recruiting 2, Recruiting 2, Terminated 2 |
Follow Ovarian Cancer: new trials by email Literature Review of Ovarian Cancer trials Research Report on Ovarian Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CYTALUX Dose Extension Study CYTALUX (pafolacianine) injection - Cancer in the Lung, Ovarian Cancer | Phase 4 | Not yet recruiting | On Target Laboratories, LLC | 106 | 2026-08-15 | 2026-08-18 |
| Study Evaluating Safety, Tolerability, and Metabolism of Niraparib Niraparib - Ovarian Cancer | Phase 4 | Recruiting | University of Miami | 70 | 2026-07-28 | 2026-08-05 |
| Near-Infrared Fluorescence Imaging With Indocyanine Green to Evaluate Bowel Anastomoses in Gynecologic Oncology Surgery Indocyanine Green, Near-Infrared Fluorescence Imaging System - Gynecologic Cancers, Ovarian Cancer | Phase 4 | Not yet recruiting | Istanbul University | 50 | 2025-09-01 | 2025-03-14 |
| The Effects of Using Different Anesthetics on the Prognosis of Primary Tumors and Its Mechanism of Action Propofol, Sevoflurane - Lung Cancer, Brain Tumor | Phase 4 | Unknown | Kaohsiung Medical University Chung-Ho Memorial Hospital | 1316 | 2023-05-23 | 2023-09-28 |
| Influences of Propofol and Sevoflurane Anesthesia in Ovarian Cancer (Anesthetics) Propofol 1%, Sevoflurane/Ultane - Ovarian Cancer | Phase 4 | Recruiting | Kaohsiung Medical University Chung-Ho Memorial Hospital | 416 | 2022-11-23 | 2023-05-30 |
| PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer Niraparib - Epithelial Ovarian Cancer, Ovarian Cancer | Phase 4 | Unknown | Seoul National University Hospital | 102 | 2022-01-01 | 2022-01-26 |
| Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy Aspirin - Venous Thromboembolism, Ovarian Cancer | Phase 4 | Completed | Duke University | 19 | 2020-08-08 | 2022-09-26 |
| A Study of Serum Folate Levels in Patients Treated With Olaparib Folic Acid Tablet - Ovarian Cancer, Breast Cancer | Phase 4 | Completed | Rush University Medical Center | 10 | 2020-07-21 | 2026-03-04 |
| Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer Olaparib - Ovarian Cancer, Breast Cancer | Phase 4 | Completed | AstraZeneca | 202 | 2020-05-25 | 2025-03-10 |
| NIraparib and Quality of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib. Niraparib - Ovarian Cancer | Phase 4 | Completed | ARCAGY/ GINECO GROUP | 141 | 2019-04-03 | 2024-12-13 |
| Diaphragmatic Resection And Gynecological Ovarian Neoplasm thoracic Drain Tube 24 Fr. - Ovarian Cancer | Phase 4 | Completed | Catholic University of the Sacred Heart | 88 | 2018-03-20 | 2020-05-22 |
| QoL-Comparison Between Trabectedin/PLD and Pt-based Therapy in Patients With Pt-sensitive Recurrent Ovarian Cancer Trabectidin (Yondelis) - Quality of Life, Ovarian Cancer | Phase 4 | Terminated | North Eastern German Society of Gynaecological Oncology | 89 | 2018-02-01 | 2025-03-20 |
| Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration in Patients With Ovarian Cancer PEG-rhG-CSF - Adjuvant Chemotherapy, Ovarian Neoplasms | Phase 4 | Terminated | Shandong University | 68 | 2017-12-01 | 2024-01-05 |
| Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates. Oral Ferrous Fumarate, Placebo - Ovarian Cancer, Cervical Cancer | Phase 4 | Completed | Sunnybrook Health Sciences Centre | 200 | 2013-11-01 | 2021-05-12 |
| Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab Bevacizumab, Paclitaxel, Carboplatin - Ovarian Cancer | Phase 4 | Unknown | National Cancer Institute, Naples | 400 | 2012-10-01 | 2023-03-24 |
| Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting fosaprepitant, aprepitant, Oral Placebo - Ovarian Cancer, Uterine Cancer | Phase 4 | Completed | Gynecologic Oncology Associates | 20 | 2011-09-01 | 2017-03-28 |
| Tranexamic Acid in Surgery of Advanced Ovarian Cancer Tranexamic acid, 0.9% NaCl solution - Ovarian Cancer | Phase 4 | Completed | Preben Kjolhede, MD, professor | 100 | 2008-03-01 | 2022-03-15 |
| Tumor Gene Expression in Women With Ovarian Cancer Dexamethasone, Placebo - Ovarian Cancer | Phase 4 | Completed | University of Chicago | 20 | 2003-01-01 | 2016-07-13 |
| A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer Neulasta (pegfilgrastim) - Neutropenia, Breast Cancer | Phase 4 | Completed | Amgen | 852 | 2002-06-01 | 2010-10-08 |
| A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment arzoxifene - Breast Cancer, Endometrial Cancer | Phase 4 | Completed | Eli Lilly and Company | 70 | 2001-01-01 | 2007-05-25 |
Ovarian Neoplasms (20) · Breast Neoplasms (4) · Lung Neoplasms (3) · Endometrial Neoplasms (2) · Uterine Cervical Neoplasms (2) · Uterine Neoplasms (2) · Anastomotic Leak (1) · Anemia (1) · Blood Loss, Surgical (1) · Brain Neoplasms (1) · Carcinoma, Ovarian Epithelial (1) · Folic Acid Deficiency (1) · Liver Neoplasms (1) · Lymphoma, Non-Hodgkin (1) · Neutropenia (1)
Adnexal Diseases (20) · Endocrine Gland Neoplasms (20) · Endocrine System Diseases (20) · Female Urogenital Diseases (20) · Female Urogenital Diseases and Pregnancy Complications (20) · Genital Diseases (20) · Genital Diseases, Female (20) · Genital Neoplasms, Female (20) · Gonadal Disorders (20) · Neoplasms (20) · Neoplasms by Site (20) · Ovarian Diseases (20) · Urogenital Diseases (20) · Urogenital Neoplasms (20) · Breast Diseases (4)
niraparib (3) · Propofol (2) · Saline Solution (2) · Sevoflurane (2) · Anesthesia, Inhalation (1) · Aprepitant (1) · Aspirin (1) · Bevacizumab (1) · Carboplatin (1) · Dexamethasone (1) · Folic Acid (1) · Indocyanine Green (1) · Injections (1) · LY 353381 (1) · Paclitaxel (1)
Kaohsiung Medical University Chung-Ho Memorial Hospital (2) · ARCAGY/ GINECO GROUP (1) · Amgen (1) · AstraZeneca (1) · Catholic University of the Sacred Heart (1) · Duke University (1) · Eli Lilly and Company (1) · Gynecologic Oncology Associates (1) · Istanbul University (1) · National Cancer Institute, Naples (1) · North Eastern German Society of Gynaecological Oncology (1) · On Target Laboratories, LLC (1) · Preben Kjolhede, MD, professor (1) · Rush University Medical Center (1) · Seoul National University Hospital (1)
United States (6) · Italy (2) · Taiwan (2) · Canada (1) · China (1) · France (1) · Germany (1) · India (1) · Nigeria (1) · Sweden (1) · Turkey (Türkiye) (1)
Zhi-Fu Wu (2) · Brittany Davidson, MD (1) · Ciro Gallo, M.D. (1) · Danielle Vicus, MD (1) · Francesco Perrone, M.D., Ph.D. (1) · Gennaro Daniele, M.D., Ph.D. (1) · Gini Fleming, MD (1) · Helena Zachrisson, MD,PhD (1) · Irene Floriani, Ph.D. (1) · Jae-Weon Jae-Weon, MD, PhD (1) · Jalid Sehouli, Prof. (1) · John P Micha, MD (1)
PMID 18165618, PMID 19383827, PMID 20118030, PMID 31586247, PMID 33931498, PMID 34462317, PMID 39415516, PMID 39673810, PMID 42575837, PMID 42851761
2018 (1)